# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Wedbush analyst Robert Driscoll reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and maintains $36 price tar...
HC Wainwright & Co. analyst Edward White reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $28 pri...
Cullinan Therapeutics, Inc. (NASDAQ:CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therap...
HC Wainwright & Co. analyst Edward White reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Buy and maintains $28 pri...
Updated data show consistent objective response rate of 40% and manageable safety profile in patients with non-small cell lun...
Merck has agreed to acquire CN201, a bispecific antibody from Curon Biopharmaceutical, for $700 million. This acquisition aims ...
Wedbush analyst Robert Driscoll reiterates Cullinan Therapeutics (NASDAQ:CGEM) with a Outperform and maintains $36 price tar...